NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis $8.71 -0.06 (-0.68%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avadel Pharmaceuticals Stock (NASDAQ:AVDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avadel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$8.64▼$8.8250-Day Range$6.59▼$8.8452-Week Range$6.38▼$19.09Volume138,627 shsAverage Volume1.22 million shsMarket Capitalization$841.64 millionP/E RatioN/ADividend YieldN/APrice Target$19.88Consensus RatingBuy Company OverviewAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More… Avadel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreAVDL MarketRank™: Avadel Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 382nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Avadel Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.51) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -10.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -10.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 8.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avadel Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.21% of the float of Avadel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.21% of the float of Avadel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment1.78 News SentimentAvadel Pharmaceuticals has a news sentiment score of 1.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Avadel Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avadel Pharmaceuticals' insider trading history. Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Stock News HeadlinesAvadel, nference announce publication of data on sodium oxybateApril 17, 2025 | markets.businessinsider.comAvadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical NeuroscienceApril 17, 2025 | globenewswire.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.April 28, 2025 | Stansberry Research (Ad)Avadel Pharmaceuticals plc (NASDAQ:AVDL) Could Be Less Than A Year Away From ProfitabilityApril 14, 2025 | finance.yahoo.comAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 10, 2025 | globenewswire.comAvadel Pharmaceuticals Provides Update at Needham Virtual Healthcare ConferenceApril 8, 2025 | globenewswire.comAvadel Pharmaceuticals Provides Update at Needham Virtual Healthcare ConferenceApril 8, 2025 | globenewswire.comAvadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare ConferenceApril 1, 2025 | globenewswire.comSee More Headlines AVDL Stock Analysis - Frequently Asked Questions How have AVDL shares performed this year? Avadel Pharmaceuticals' stock was trading at $10.51 on January 1st, 2025. Since then, AVDL shares have decreased by 17.6% and is now trading at $8.6610. View the best growth stocks for 2025 here. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its earnings results on Tuesday, November, 12th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. Avadel Pharmaceuticals's revenue was up 624.6% on a year-over-year basis. Read the conference call transcript. Who are Avadel Pharmaceuticals' major shareholders? Top institutional investors of Avadel Pharmaceuticals include Wealth Effects LLC (2.45%), Rhumbline Advisers (0.13%), IMC Chicago LLC and Edge Wealth Management LLC (0.03%). Insiders that own company stock include Eric J Ende, Peter J Thornton, Thomas S Mchugh, Geoffrey Michael Glass, Geoffrey Michael Glass, Linda Palczuk, Mark Anthony Mccamish and Gregory J Divis. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX). Company Calendar Last Earnings11/12/2024Today4/27/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVDL CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees70Year Founded2015Price Target and Rating Average Stock Price Target$19.88 High Stock Price Target$30.00 Low Stock Price Target$12.00 Potential Upside/Downside+126.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,280,000.00 Net Margins-52.53% Pretax Margin-52.84% Return on Equity-93.34% Return on Assets-44.77% Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.60 Sales & Book Value Annual Sales$169.12 million Price / Sales5.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book8.95Miscellaneous Outstanding Shares96,629,000Free Float91,737,000Market Cap$847.44 million OptionableOptionable Beta1.52 Social Links 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:AVDL) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.